Guidelines for the Diagnosis and Management of Asthma. National Asthma Education and Prevention Program Expert Panel, NIH, February, 1997

1997 ◽  
Vol 36 (12) ◽  
pp. 722-723
Author(s):  
David J. Birnkrant
Keyword(s):  
Prevention Program ◽  
Expert Panel ◽  
Asthma Education ◽  
Diagnosis And Management

Asthma

2014 ◽  
pp. 315-324
Author(s):  
Christopher H. Fanta
Keyword(s):  
Prevention Program ◽  
Expert Panel ◽  
Airflow Obstruction ◽  
Bronchial Hyperresponsiveness ◽  
Clinical Manifestations ◽  
Response To Treatment ◽  
Asthma Education ◽  
Chronic Disorder ◽  
Underlying Inflammation

The 2007 National Asthma Education and Prevention Program Expert Panel defines asthma as “a common chronic disorder of the airways that is complex and characterized by variable and recurring symptoms, airflow obstruction, bronchial hyperresponsiveness, and an underlying inflammation. The interaction of these features of asthma determines the clinical manifestations and severity of asthma and the response to treatment.”

scholarly journals National Asthma Education and Prevention Program 2020 Guidelines: What’s Important for Primary Care

2021 ◽  
Vol 70 (6 Supplement) ◽  
Author(s):  
Murphy
Keyword(s):  
Primary Care ◽  
Prevention Program ◽  
Expert Panel ◽  
Asthma Management ◽  
Persistent Asthma ◽  
Asthma Severity ◽  
Asthma Education ◽  
Global Initiative For Asthma ◽  
Primary Care Clinicians ◽  
Global Initiative

KEY TAKEAWAYS • The 2020 Focused Updates to the Asthma Management Guidelines: A Report from the National Asthma Education and Prevention Program Coordinating Committee Expert Panel Working Group provides updated recommendations for 6 topics related to the management of individuals with asthma. • The classification of asthma severity and asthma control, as well as the concept of utilizing a stepwise approach to pharmacologic treatment, were not updated from the Expert Panel Report 3, released in 2007. • However, important updates in preferred therapies for intermittent and persistent asthma at treatment steps 1 through 5 were suggested. • Recommendations regarding biologic therapy were not included in the 2020 update, as only evidence and US Food and Drug Administration approvals through October 2018 were considered. • The most recent 2021 Global Initiative for Asthma guidelines are not included in this review but can be used in a complementary manner to assist primary care clinicians to optimize decisions regarding the care of patients with asthma.

Sign in / Sign up

Export Citation Format

Share Document